On the basis of scientific conditions, the Medicines Evaluation Board (MEB) will draw up a list of medicines for which switching is undesirable. It will do this in the interests of patient safety. Medicines with the same active ingredient, dosage and method of administration are usually interchangeable. Nevertheless, the exchange regularly leads to restlessness, dissatisfaction or even health complaints.
MEB will finalize this list by the end of 2020.
Will this impact the generic market and increase the impact of shortages?